Acute effect of pretreatment with single conventional dose of salmeterol on dose-response curve to oxitropium bromide in chronic obstructive pulmonary disease

被引:11
|
作者
Cazzola, M
Di Perna, F
Centanni, S
Califano, C
Donner, CF
D'Amato, M
D'Amato, G
机构
[1] A Cardarelli Hosp, Div Pneumol & Allergol, Naples, Italy
[2] Univ Milan, Sch Med, San Paolo Hosp, Resp Dis Unit, Milan, Italy
[3] S Maugeri Fdn, Inst Care & Res, Med Ctr Rehabil, Div Pneumol, Veruno, Italy
关键词
salmeterol; oxitropium bromide; combination therapy; chronic obstructive pulmonary disease;
D O I
10.1136/thx.54.12.1083
中图分类号
R56 [呼吸系及胸部疾病];
学科分类号
摘要
Background-An earlier study documented that, in patients with chronic obstructive pulmonary disease (COPD), addition of ipratropium bromide at the clinically recommended dose (40 mu g) does not produce any further bronchodilation than that achieved with salmeterol 50 mu g alone. However, the dose of ipratropium bromide needed to produce near maximal bronchodilation is several times higher than the customary dosage. The full therapeutic potential of combined salmeterol plus an anticholinergic drug can therefore only be established using doses higher than those currently recommended in the marketing of these agents. A study was undertaken to examine the possible acute effects of higher than conventional doses of an anticholinergic agent on the single dose salmeterol induced bronchodilation in patients with stable and partially reversible COPD. Methods-Thirty two outpatients received 50 pg salmeterol or placebo. Two hours after inhalation a dose-response curve to inhaled oxitropium bromide (100 mu g/puff) or placebo was constructed using one puff, one puff, two puffs, and two puffs-that is, a total cumulative dose of 600 mu g oxitropium bromide. Dose increments were given at 20 minute intervals with measurements being made 15 minutes after each dose. On four separate days all patients received one of the following: (1) 50 pg salmeterol + 600 pg oxitropium bromide; (2) 50 pg salmeterol + placebo; (3) placebo + 600 pg oxitropium bromide; (4) placebo + placebo. Results-Salmeterol induced a good bronchodilation (mean increase 0.272 1; 95% CI 0.207 to 0.337) two hours after its inhalation. Oxitropium bromide elicited an evident dose-dependent increase in forced expiratory volume in one second (FEV1) and this occurred also after pretreatment with salmeterol with a further mean maximum increase of 0.152 1 (95% CI of differences 0.124 to 0.180). Conclusions-This study shows that acute pretreatment with 50 pg salmeterol does not block the possibility of inducing more bronchodilation with an anticholinergic agent when a higher than normal dosage of the muscarinic antagonist is used.
引用
收藏
页码:1083 / 1086
页数:4
相关论文
共 50 条
  • [1] DOSE-RESPONSE STUDY OF OXITROPIUM BROMIDE INHALED AS A NEBULIZED SOLUTION
    STAPPAERTS, I
    VANSCHIL, L
    VANDERVEKEN, J
    EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY, 1994, 46 (04) : 305 - 307
  • [2] Effect of salmeterol on the ventilatory response to exercise in chronic obstructive pulmonary disease
    O'Donnell, DE
    Voduc, N
    Fitzpatrick, M
    Webb, KA
    EUROPEAN RESPIRATORY JOURNAL, 2004, 24 (01) : 86 - 94
  • [3] Longitudinal FEV1 dose-response model for inhaled PF-00610355 and salmeterol in patients with chronic obstructive pulmonary disease
    Nielsen, Jace C.
    Hutmacher, Matthew M.
    Cleton, Adriaan
    Martin, Steven W.
    Ribbing, Jakob
    JOURNAL OF PHARMACOKINETICS AND PHARMACODYNAMICS, 2012, 39 (06) : 619 - 634
  • [4] Low-dose Fluticasone Propionate in Combination With Salmeterol in Patients With Chronic Obstructive Pulmonary Disease
    Yasui, Hideki
    Inui, Naoki
    Fujisawa, Tomoyuki
    Karayama, Masato
    Enomoto, Noriyuki
    Nakamura, Yutaro
    Kuroishi, Shigeki
    Ohba, Hisano
    Yokomura, Koshi
    Sato, Jun
    Sato, Masaki
    Koshimizu, Naoki
    Toyoshima, Mikio
    Yamada, Takashi
    Masuda, Masafumi
    Shirai, Toshihiro
    Suda, Takafumi
    CLINICAL MEDICINE INSIGHTS-CIRCULATORY RESPIRATORY AND PULMONARY MEDICINE, 2018, 12
  • [5] Comparison of the bronchodilating effect of salmeterol and zafirlukast in combination with that of their use as single treatments in asthma and chronic obstructive pulmonary disease
    Cazzola, M
    Centanni, S
    Boveri, B
    Di Marco, F
    Santus, P
    Matera, MG
    Allegra, L
    RESPIRATION, 2001, 68 (05) : 452 - 459
  • [6] Dose-response curve to salbutamol during acute and chronic treatment with formoterol in COPD
    La Piana, Giuseppe Emanuele
    Corda, Luciano
    Bertella, Enrica
    Montemurro, Luigi Taranto
    Pini, Laura
    Tantucci, Claudio
    INTERNATIONAL JOURNAL OF CHRONIC OBSTRUCTIVE PULMONARY DISEASE, 2011, 6 : 399 - 405
  • [7] COMPARATIVE DOSE-RESPONSE STUDY OF 3 ANTICHOLINERGIC AGENTS AND FENOTEROL USING A METERED-DOSE INHALER IN PATIENTS WITH CHRONIC OBSTRUCTIVE PULMONARY-DISEASE
    IKEDA, A
    NISHIMURA, K
    KOYAMA, H
    IZUMI, T
    THORAX, 1995, 50 (01) : 62 - 66
  • [8] Body mass index and mortality in chronic obstructive pulmonary disease A dose-response meta-analysis
    Guo, Yibin
    Zhang, Tianyi
    Wang, Zhiyong
    Yu, Feifei
    Xu, Qin
    Guo, Wei
    Wu, Cheng
    He, Jia
    MEDICINE, 2016, 95 (28)
  • [9] Efficacy and Safety Analysis of Salmeterol/Fluticasone Propionate with Tiotropium Bromide for Chronic Obstructive Pulmonary Disease
    Zhang, Zili
    INDIAN JOURNAL OF PHARMACEUTICAL SCIENCES, 2024, 86 : 128 - 133
  • [10] EFFECT OF SALMETEROL AND FORMOTEROL IN PATIENTS WITH CHRONIC OBSTRUCTIVE PULMONARY-DISEASE
    CAZZOLA, M
    SANTANGELO, G
    PICCOLO, A
    SALZILLO, A
    MATERA, MG
    DAMATO, G
    ROSSI, F
    PULMONARY PHARMACOLOGY, 1994, 7 (02): : 103 - 107